Full Text View
Tabular View
No Study Results Posted
Related Studies
Capecitabine and Paclitaxel in Treating Patients With Metastatic Breast Cancer
This study is ongoing, but not recruiting participants.
First Received: March 8, 2002   Last Updated: July 23, 2008   History of Changes
Sponsored by: Swiss Group for Clinical Cancer Research
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT00031876
  Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase I/II trial to determine the effectiveness of combining capecitabine and paclitaxel in treating patients who have metastatic breast cancer.


Condition Intervention Phase
Breast Cancer
 Drug: capecitabine
Drug: paclitaxel
 Phase I
Phase II

Study Type: Interventional
Study Design: Treatment
Official Title: Phase I/II Trial of Capecitabine With Weekly Paclitaxel for Advanced Breast Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: Paclitaxel Capecitabine
U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date: May 2000
Detailed Description:

OBJECTIVES:

  • Determine the maximum tolerated dose (MTD) of capecitabine when combined with paclitaxel in patients with metastatic adenocarcinoma of the breast.
  • Determine the clinical efficacy of the dose immediately preceding the MTD identified in phase I, in terms of response rate, time to treatment failure, time to disease progression, and overall survival, in these patients.
  • Determine the toxicity of this regimen in these patients.
  • Determine a well-tolerated drug combination for these patients.

OUTLINE: This is a dose-escalation, multicenter study of capecitabine.

Patients receive oral capecitabine twice daily on days 1-14 and paclitaxel IV over 1 hour on days 1, 8, and 15. Treatment repeats every 21 days for a maximum of 6 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 or more of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at the dose level immediately preceding the MTD.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 3-24 patients will be accrued for phase I and 15-46 patients will be accrued for phase II of this study.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed metastatic adenocarcinoma of the breast

  • Patients in phase I:

    • Evaluable disease

  • Patients in phase II:

    • Bidimensionally measurable disease

      • Bone metastases are not considered measurable
  • No known or clinically suspected CNS metastases

  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age:

  • 18 to 64

Sex:

  • Not specified

Menopausal status:

  • Not specified

Performance status:

  • WHO 0-2

Life expectancy:

  • At least 12 weeks

Hematopoietic:

  • WBC greater than 3,500/mm^3
  • Platelet count greater than 100,000/mm^3
  • Hemoglobin at least 10 g/dL

Hepatic:

  • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
  • AST/ALT no greater than 2 times ULN (3 times ULN if liver metastases present)

Renal:

  • Patients in phase I:

    • Creatinine clearance at least 50 mL/min

  • Patients in phase I or II:

    • Creatinine no greater than 1.5 times ULN

Cardiovascular:

  • No grade 2 or greater atrioventricular block

Other:

  • No cognitive impairment or severe psychiatric disorder
  • No greater than grade 2 preexisting peripheral neuropathy
  • No other prior or concurrent malignancy except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
  • Able to tolerate steroid premedication

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • Not specified

Chemotherapy:

  • More than 6 months since prior adjuvant chemotherapy
  • At least 1 year since prior continuous infusion of fluorouracil or capecitabine
  • At least 1 year since prior taxane administered once every 3 weeks
  • No prior taxane or capecitabine administered weekly
  • No more than 1 prior chemotherapy regimen for metastatic or locally advanced breast cancer
  • No other concurrent chemotherapy

Endocrine therapy:

  • Prior hormonal treatment for metastatic breast cancer allowed
  • No concurrent continuous glucocorticosteroids
  • No concurrent systemic endocrine treatment for breast cancer

Radiotherapy:

  • No concurrent radiotherapy to indicator lesion or more than 30% of bone marrow

Surgery:

  • Not specified

Other:

  • No other concurrent anticancer treatment
  • No concurrent immunosuppressive drugs
  • Concurrent bisphosphonates allowed if indicator lesion is non-bone
  • Able to tolerate steroid premedication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00031876

Locations
Switzerland
Inselspital, Bern
Bern, Switzerland, CH-3010
UniversitaetsSpital
Zurich, Switzerland, CH-8091
Sponsors and Collaborators
Swiss Group for Clinical Cancer Research
Investigators
Study Chair: Stefan Aebi, MD University Hospital Inselspital, Berne
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

Publications:
Gick U, Rochlitz C, Mingrone W, Pestalozzi B, Rauch D, Ballabeni P, Lanz D, Hess V, Aebi S. Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK. Oncology. 2006;71(1-2):54-60. Epub 2007 Mar 5.
Uhlmann C, Ballabeni P, Rijken N, Brauchli P, Mingrone W, Rauch D, Pestalozzi BC, Rochlitz C, Aebi S; Swiss Group for Clinical Cancer Research; Swiss Institute for Applied Cancer Research. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. Oncology. 2004;67(2):117-22.

Study ID Numbers: CDR0000069236, SWS-SAKK-26/00, EU-20135
Study First Received: March 8, 2002
Last Updated: July 23, 2008
ClinicalTrials.gov Identifier: NCT00031876     History of Changes
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
stage IV breast cancer
recurrent breast cancer

Study placed in the following topic categories:
Antimetabolites
Capecitabine
Skin Diseases
Paclitaxel
Tubulin Modulators
 Breast Neoplasms
Antimitotic Agents
Antineoplastic Agents, Phytogenic
Breast Diseases
Recurrence

Additional relevant MeSH terms:
Antimetabolites
Capecitabine
Antimetabolites, Antineoplastic
Skin Diseases
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Mitosis Modulators
Breast Neoplasms
Antimitotic Agents
 Pharmacologic Actions
Neoplasms
Neoplasms by Site
Paclitaxel
Therapeutic Uses
Tubulin Modulators
Antineoplastic Agents, Phytogenic
Breast Diseases

ClinicalTrials.gov processed this record on July 02, 2009



Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services